CTOs on the Move

20/20 GeneSystems Inc

www.2020gene.com

 
20/20 GeneSystems Inc is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.2020gene.com
  • 9430 Key West Ave
    Rockville, MD USA 20850
  • Phone: 240.453.6339

Executives

Name Title Contact Details

Similar Companies

Autem Therapeutics

Autem Therapeutics is a privately held oncology therapeutic and bioelectric company headquartered in Hanover NH, USA that is developing a novel, non-invasive and non-toxic oncology treatment platform targeting HCC (liver cancer) and other solid tumor cancers.

Rhythm Pharmaceuticals

Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity.

SomaLogic

Revolutionizing Proteomics To Transform Healthcare SomaLogic was founded in 2000 with the goal of improving the well-being and quality of life of every individual by transforming how diseases were detected and diagnosed. Building on the previous decade of aptamer research, SomaLogic scientists have developed a new proteomics technology that overcomes the significant challenges of current technologies, and which has multiple applications across the biological and medical sciences. Our mission is to leverage our proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare.

ChemDiv

ChemDiv is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tizona Therapeutics

Tizona Therapeutics, Inc. is a preclinical stage biotechnology company that is developing multiple, innovative immuno-oncology therapies. Tizona Therapeutics, Inc. was founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women`s Hospital.